Abstract:Abstract Background: Copper metabolism is frequently dysregulated in cancer and promotes tumorigenesis. Copper chelation was shown to delay tumor development, attenuate tumor growth, block angiogenesis and inhibit metastases in preclinical breast cancer models. Copper depletion with tetrathiomolybdate (TM) in on-going phase II study for breast cancer patients at high risk for relapse resulted in significant improvement in progression-free survival, especially in patients with TNBC. We hypothesized that targeting ATOX-1 and CCS, copper chaperons that are major regulators of copper trafficking, with novel selective inhibitor may disrupt cellular copper transport and suppress TNBC cell growth, block angiogenic activity, and enhance cytotoxicity of available chemotherapy. Methods:We measured ATOX-1 and CCS protein expression using western blot in a panel of breast cancer cell lines including TNBC cell lines with basal-like (BL) and claudin-low (CL) subtypes. We compared potency and efficacy of ATOX-1/CCS inhibitor to induce cytotoxicity in MDA-MB231, MDA-MB436, MDA-MB468 and primary normal mammary HMECs. We evaluated ability of the inhibitor to disrupt tubulogenesis of endothelial cells. To determine if blocking copper transport can enhance sensitivity of TNBC to chemotherapy we used novel ATOX-1/CCS inhibitor in combination with Cisplatin to treat TNBC in a schedule-dependent manner. Results: ATOX-1 protein expression was elevated in all tested TNBC cell lines compared to normal HMEC (1.7±0.2 and 2.1± 0.3 folds higher in BL and CL cells, respectively). Upregulated CCS protein expression was also observed in majority of tested cell lines compared to HMEC (2.8±0.6 and 1.2±0.1 times higher in BL and CL cells, respectively). Treatment of MDA-MB231, MDA-MB436, MDA-MB468 with the inhibitor resulted in reduced cell proliferation. IC50 doses for 72h treatment with single agent were: 0.23±0.02uM (MDA-MB468), 0.29±0.03uM (MDA-MB231) and 0.35±0.02uM (MDA-MB436). Additional cytotoxicity was observed in TNBC when ATOX-1/CCS inhibitor was applied in combination with Cisplatin. Interestingly, sequential treatment resulted in synergistic effect (CI< 1). Treatment with the inhibitor reduced growth of HMECs and HuVECs in vitro, and inhibited angiogenesis in tube formation assay with HuVECs. Conclusions: Targeting copper trafficking by selective inhibition of chaperons ATOX-1 and CCS is promising and could potentially serve as a therapeutic approach to overcome resistance to chemotherapy in TNBC. In vivo studies investigating efficacy and biological activity of the novel compound in a xenograft model are ongoing and will help to elucidate molecular mechanisms of action, and further estimate potential clinical relevance of this approach. Citation Format: Karginova O, Song A, Wang J, Luo C, Jiang H, He C, Olopade OI. Copper chaperons as novel targets for therapy in triple-negative breast cancer (TNBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-04-09.

Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers

Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

Blockade of TGF-βR improves the efficacy of doxorubicin by modulating the tumor cell motility and affecting the immune cells in a melanoma model

Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Influence of TLR4 signaling on Cannabidiol's antitumor effectiveness in lung adenocarcinoma cells

Abstract PO3-25-11: Unprecedented responses to neoadjuvant sequential administration of Tocilizumab followed by cisplatin/docetaxel for locally advanced triple negative breast cancer patients

Data from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands

Abstract B023: Immunomodulatory telodendrimer nanomedicine in treating ovarian cancer

Abstract 1810: Enhanced anti-breast tumor cancer activity using nano-formulated TLR 7/8 agonist and PI3K inhibitor

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands

Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis

Enhanced Apoptotic Effects in MDA-MB-231 Triple-Negative Breast Cancer Cells Through a Synergistic Action of Luteolin and Paclitaxel

Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability

Abstract P5-04-09: Copper Chaperons As Novel Targets for Therapy in Triple-Negative Breast Cancer (TNBC)

Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells

Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model

MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells

Abstract 2325: Targeting kynurenine pathway using novel IDO/TDO dual inhibitor (AT0174) to modulate tumor microenvironment in platinum resistant non-small cell lung cancer cancer: An immunometabolism compliment markers

Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment